Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant
NCT00526292
Completed
The goal of this study is to see if there is a benefit to giving chemotherapy and then natural killer (NK) cells. The NK cells must come from a family member who shares half of the patients HLA proteins. NK cells are a type of white blood cell. They can recognize and kill abnormal cells in the body. Patients whose blood cancer is not cured with a stem cell transplant do not have standard treatment options. Studies have shown that NK cells from a donor can be given safely and can be helpful in t... Read More
Gender:
ALL
Ages:
120 years and below
Trial Updated:
01/14/2016
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Leukemia, Myelodysplastic Syndromes
Register for Updates
Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT00280241
Completed
This research study will look at the effects (good or bad) of administering cyclophosphamide, fludarabine, and rituximab. Clinical studies with combination therapy have shown higher response rates than using single drugs, and this study will evaluate the side effects and effectiveness of this combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/05/2016
Locations: Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
NCT00387959
Completed
RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine, total-body irradiation, and rituximab before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/22/2015
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Leukemia, Lymphoma
Register for Updates
A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)
NCT00592111
Completed
Study Hypothesis: Clinical staging without laparotomy/splenectomy is adequate for children and young adults with Hodgkin's disease who receive chemotherapy as a component of treatment.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
12/21/2015
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Pediatric, Hodgkin's Disease
Register for Updates
Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer
NCT00028730
Completed
RATIONALE: Giving chemotherapy and total body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
12/21/2015
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Register for Updates
Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility
NCT00617370
Completed
The purpose of this study is to give a drug regimen that is hoped to be effective in preventing cancer from coming back. Since it is an aggressive breast cancer, there is a moderate to high chance that the cancer may come back. The standard treatment for this tumor type includes a chemotherapy regimen with drugs named epirubicin (E) and cyclophosphamide (C) in a vein every 2 weeks for 4 treatments, followed by a drug named paclitaxel, every 2 weeks in your vein for 4 treatments. This study is a... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/21/2015
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Breast Cancer, Adenocarcinoma of the Breast
Register for Updates
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
NCT00890955
Completed
Amrubicin has shown single-agent activity in lung cancer. The combination of cyclophosphamide and anthracyclines has been studied and concluded that the combination was tolerable, could be given safely, and therapeutically useful. This Phase I study will evaluate the combination of cyclophosphamide with amrubicin in relapsed solid tumors and will define the MTD of the combination in a US population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/21/2015
Locations: Highlands Oncology Group, Springdale, Arkansas +9 locations
Conditions: Lung Cancer
Register for Updates
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
NCT00002718
Completed
RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of T-cell depleted bone marrow and G-CSF stimulated peripheral stem cell transplantation in treating patients with leukemia, lymphoblastic lymphoma, myelodysplastic syndrome, or aplastic anemia.
Gender:
ALL
Ages:
49 years and below
Trial Updated:
12/21/2015
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Register for Updates
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
NCT00084838
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving intrathecal and systemic combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed central nervous system (CNS)... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
12/18/2015
Locations: Stanford Cancer Center, Stanford, California +11 locations
Conditions: Central Nervous System Tumor, Pediatric
Register for Updates
Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
NCT00003631
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus radiation th... Read More
Gender:
ALL
Ages:
120 years and below
Trial Updated:
12/17/2015
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Lymphoma
Register for Updates
FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia
NCT00381004
Completed
The goal of this clinical research study is to learn if using a combination of fludarabine, cyclophosphamide, and rituximab, with sargramostim (GM-CSF) can help to control previously untreated chronic lymphocytic leukemia (CLL). The safety of this combination will also be studied. This study will evaluate antibody-dependent cellular cytotoxicity (ADCC) and its relationship to response.
Gender:
ALL
Ages:
All
Trial Updated:
12/14/2015
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
NCT00235235
Terminated
The proposed trial provides a unique opportunity in that it combines genomic, proteomic, and pharmacogenomic assessments in patients receiving the most commonly used chemotherapies for advanced breast cancer. To date no other trial has analyzed gene and protein expression at the same time points in the same patient, combined with clinical outcome. Similar to previous attempts to predict response based on expression of a single gene or protein, the researchers expect that neither genomic or prote... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/08/2015
Locations: Cancer Care Center of Southern Indiana, Bloomington, Indiana +10 locations
Conditions: Breast Cancer
Register for Updates